NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes

Novo Nordisk A/S513 enrolled

Overview

This trial is conducted in the United States of America (USA). The aim of this trial is to assess control of blood sugar, safety, and patient acceptance of insulin aspart compared to insulin lispro, both in insulin pumps, in standard clinical practice.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

513

Conditions

Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2

Interventions

insulin aspartDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * People with Type I or Type II Diabetes * 18 Years or Older.

Locations (1)

Novo Nordisk Investigational Site

Princeton, New Jersey, United States

Outcomes

Primary Outcomes

Treatment satisfaction with insulin pump therapy

Secondary Outcomes

body weight

Insulin dose

Overall glycemic control

number and types of infusion sets used.

infusion set in-use times

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.